Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist.
暂无分享,去创建一个
[1] S. Mizel,et al. The interleukin 1 receptor. Dynamics of interleukin 1 binding and internalization in T cells and fibroblasts. , 1987, Journal of immunology.
[2] G. Higgins,et al. Interleukin 1 beta propeptide is detected intracellularly and extracellularly when human monocytes are stimulated with LPS in vitro , 1994, The Journal of experimental medicine.
[3] C. Dinarello,et al. Interleukin‐1 (IL‐1) receptor blockade reduces endotoxin and Borrelia burgdorferi‐stimulated IL‐8 synthesis in human mononuclear cells , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[4] J. Symons,et al. Purification and characterization of a novel soluble receptor for interleukin 1 , 1991, The Journal of experimental medicine.
[5] M. Stoeckle,et al. High-resolution analysis of groα mRNA poly(A) shortening: regulation by interleukin-1β , 1993 .
[6] W. Leisenring,et al. Aplastic anemia: analysis of stromal cell function in long-term marrow cultures. , 1994, Blood.
[7] A. Heguy,et al. The chicken IL-1 receptor: differential evolution of the cytoplasmic and extracellular domains. , 1992, Gene.
[8] P. Bongrand,et al. Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. , 1994, Blood.
[9] T. Vischer,et al. Inhibitors of interleukin 1 activity in synovial fluids and in cultured synovial fluid mononuclear cells. , 1992, The Journal of rheumatology.
[10] W. Arend. Interleukin-1 receptor antagonist. , 1993, Advances in immunology.
[11] B. Brandhuber,et al. X-ray structure of interleukin-1 receptor antagonist at 2.0-A resolution. , 1995, The Journal of biological chemistry.
[12] P. Fabri,et al. Decreased Mortality of Severe Acute Pancreatitis After Proximal Cytokine Blockade , 1995, Annals of surgery.
[13] R. Black,et al. Human keratinocytes produce but do not process pro-interleukin-1 (IL-1) beta. Different strategies of IL-1 production and processing in monocytes and keratinocytes. , 1991, The Journal of clinical investigation.
[14] J. Banchereau,et al. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. , 1995, Journal of immunology.
[15] S. Wolff. Biological effects of bacterial endotoxins in man. , 1973, The Journal of infectious diseases.
[16] R. Horuk,et al. Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor. , 1990, The Journal of biological chemistry.
[17] R. Locksley,et al. Interleukin 1: The patterns of translation and intracellular distribution support alternative secretory mechanisms , 1992, Journal of cellular physiology.
[18] A. Billiau,et al. Interferon gamma, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice , 1990, The Journal of experimental medicine.
[19] J. Saurat,et al. Interleukin 1 is present in normal human epidermis. , 1986, Journal of immunology.
[20] J. Mier,et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. , 1992, Cytokine.
[21] H. Tilg,et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. , 1994, Blood.
[22] D. Dripps,et al. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. , 1991, The Journal of biological chemistry.
[23] F. Murad,et al. Identification of multiple binding sites for atrial natriuretic factor by affinity cross-linking in cultured endothelial cells. , 1986, The Journal of biological chemistry.
[24] M. Labow,et al. Molecular Cloning and Characterization of a Second Subunit of the Interleukin 1 Receptor Complex (*) , 1995, The Journal of Biological Chemistry.
[25] K. Prickett,et al. The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor. , 1987, The Journal of biological chemistry.
[26] R. Thompson,et al. Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits , 1993, Infection and immunity.
[27] S. Gabriel,et al. Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report on nineteen cases. , 1996, Arthritis and rheumatism.
[28] R. F. Johnston,et al. Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .
[29] M. Busslinger,et al. Alternative promoter usage of the Fos‐responsive gene Fit‐1 generates mRNA isoforms coding for either secreted or membrane‐bound proteins related to the IL‐1 receptor. , 1994, The EMBO journal.
[30] N. Copeland,et al. Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1 beta-converting enzyme. , 1994, Genes & development.
[31] K. Resch,et al. Two‐chain structure of the interleukin 1 receptor , 1988, FEBS letters.
[32] S. Jobling,et al. A point mutation uncouples human interleukin-1 beta biological activity and receptor binding. , 1990, The Journal of biological chemistry.
[33] T. van der Poll,et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. , 1990, The New England journal of medicine.
[34] S. Brown,et al. Identification of a nuclear localization sequence within the structure of the human interleukin-1 alpha precursor. , 1993, The Journal of biological chemistry.
[35] A. Heguy,et al. Amino acids conserved in interleukin-1 receptors (IL-1Rs) and the Drosophila toll protein are essential for IL-1R signal transduction. , 1992, The Journal of biological chemistry.
[36] R. Black,et al. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase , 1991, The Journal of experimental medicine.
[37] H. Stunnenberg,et al. Low Affinity Binding of Interleukin-1 and Intracellular Signaling via NF-B Identify Fit-1 as a Distant Member of the Interleukin-1 Receptor Family (*) , 1995, The Journal of Biological Chemistry.
[38] G. Firestein,et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. , 1994, Arthritis and rheumatism.
[39] A. Puren,et al. Studies on IL-1 receptors on D10S T-helper cells: demonstration of two molecularly and antigenically distinct IL-1 binding proteins. , 1989, Cytokine.
[40] R. Sitia,et al. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. , 1992, The Journal of biological chemistry.
[41] C. Nast,et al. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. , 1994, The Journal of clinical investigation.
[42] C. Dinarello,et al. Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia. , 1993, Archives of surgery.
[43] M. Weitzmann,et al. Nuclear internalisation and DNA binding activities of interleukin-1, interleukin-1 receptor and interleukin-1/receptor complexes. , 1992, Biochemical and Biophysical Research Communications - BBRC.
[44] T. Hopp. Evidence from sequence information that the interleukin‐1 receptor is a transmembrane GTPase , 1995, Protein science : a publication of the Protein Society.
[45] J. Saklatvala,et al. Murine interleukin‐1 receptor: Differences in binding properties between fibroblastic and thymoma cells and evidence for a two‐chain receptor model , 1987, FEBS letters.
[46] M. Fishman,et al. Prevention of vertebrate neuronal death by the crmA gene. , 1994, Science.
[47] L. Lachman,et al. Subcellular localization of human monocyte interleukin 1: evidence for an inactive precursor molecule and a possible mechanism for IL 1 release. , 1987, Journal of immunology.
[48] C. Dinarello,et al. Histamine enhances interleukin (IL)-1-induced IL-1 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. Comparison with IL-1 receptor antagonist. , 1993, The Journal of clinical investigation.
[49] J. Singer,et al. Phase I study of recombinant interleukin-1 beta in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. , 1994, Blood.
[50] D. Roeder,et al. Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. , 1990, Science.
[51] I. Olsson,et al. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. , 1993, Cancer research.
[52] M. Tocci,et al. IL-1 beta convertase (ICE) does not play a requisite role in apoptosis induced in T lymphoblasts by Fas-dependent or Fas-independent CTL effector mechanisms. , 1997, Journal of immunology.
[53] R. Bone,et al. Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.
[54] K. Matsushima,et al. Human pre-interleukin 1 alpha and beta: structural features revealed by limited proteolysis. , 1991, Chemical & pharmaceutical bulletin.
[55] C J Fisher,et al. The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. , 1993, JAMA.
[56] M Kurimoto,et al. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. , 1997, Journal of immunology.
[57] T. Fahey,et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[58] T. J. Hayes,et al. Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. , 1991, The American journal of physiology.
[59] D. Hazuda,et al. Processing of precursor interleukin 1 beta and inflammatory disease. , 1990, The Journal of biological chemistry.
[60] A. Schmitz,et al. A mutational analysis of receptor binding sites of interleukin-1β:differences in binding of human interleukin-1β muteins to human and mouse receptors , 1994 .
[61] J. Voorhees,et al. Interleukin-1 receptor antagonist in normal and psoriatic epidermis. , 1992, The Journal of clinical investigation.
[62] B. Ryffel,et al. Interferon gamma receptor deficient mice are resistant to endotoxic shock , 1994, The Journal of experimental medicine.
[63] M. Gayle,et al. Interleukin 1 signaling occurs exclusively via the type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[64] J. Suttles,et al. Evidence against the existence of a membrane form of murine IL-1 alpha. , 1989, Journal of immunology.
[65] P. Ghezzi,et al. Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells. , 1991, Cytokine.
[66] R. Buller,et al. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein , 1992, Cell.
[67] Y. Kobayashi,et al. Selective release of a processed form of interleukin 1 alpha. , 1994, Cytokine.
[68] Junying Yuan,et al. Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3 , 1993, Cell.
[69] R. Black,et al. Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor. , 1988, The Journal of biological chemistry.
[70] A. C. Webb,et al. Studies on the molecular nature of human interleukin 1. , 1987, Journal of immunology.
[71] R. Kaempfer,et al. Induction of human interleukin-1 gene expression by retinoic acid and its regulation at processing of precursor transcripts. , 1994, The Journal of biological chemistry.
[72] H. Kawasaki,et al. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[73] L. Rawlinson,et al. Interleukin 1 induces NF-kappa B through its type I but not its type II receptor in lymphocytes. , 1992, The Journal of biological chemistry.
[74] D. Hazuda,et al. Structure-function mapping of interleukin 1 precursors. Cleavage leads to a conformational change in the mature protein. , 1991, The Journal of biological chemistry.
[75] W. Arend,et al. Enhanced production of IL-1 receptor antagonist by alveolar macrophages from patients with interstitial lung disease. , 1993, The American review of respiratory disease.
[76] C. Dinarello,et al. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. , 1990, Blood.
[77] M. Su,et al. Cleavage of Poly(ADP-ribose) Polymerase by Interleukin-1β Converting Enzyme and Its Homologs TX and Nedd-2 (*) , 1995, The Journal of Biological Chemistry.
[78] T. Ikejima,et al. Glycosylation of the interleukin-1 receptor type I is required for optimal binding of interleukin-1. , 1992, Lymphokine and cytokine research.
[79] P. Fabri,et al. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. , 1995, Surgery.
[80] H. Okamura,et al. Cloning of a new cytokine that induces IFN-γ production by T cells , 1995, Nature.
[81] W. Urba,et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] H. Macdonald,et al. Granzyme A is an interleukin 1 beta-converting enzyme , 1995, The Journal of experimental medicine.
[83] U. Andersson,et al. Lipopolysaccharide induces human interleukin‐1 receptor antagonist and interleukin‐1 production in the same cell , 1992, European journal of immunology.
[84] J. Bray,et al. Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 beta by site-directed mutagenesis. Identification of a single site in IL-1ra and two sites in IL-1 beta , 1995, The Journal of Biological Chemistry.
[85] L. Shapiro,et al. Ciliary Neurotrophic Factor Combined with Soluble Receptor Inhibits Synthesis of Proinflammatory Cytokines and Prostaglandin-E2in Vitro , 1994 .
[86] E. Qwarnstrom,et al. IL-1 and its receptor are translocated to the nucleus. , 1990, Journal of immunology.
[87] A. C. Webb,et al. Biological activity and receptor binding of human prointerleukin-1 beta and subpeptides. , 1988, The Journal of biological chemistry.
[88] L. Mahan,et al. Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice. , 1991, The Journal of clinical investigation.
[89] S. Opal,et al. Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial , 1994, Critical care medicine.
[90] C. Nast,et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. , 1990, The Journal of clinical investigation.
[91] C. March,et al. Molecular cloning of the interleukin-1 beta converting enzyme. , 1992, Science.
[92] L. Shapiro,et al. Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. , 1993, The Journal of infectious diseases.
[93] J. Weidner,et al. The interleukin-1 beta-converting enzyme (ICE) is localized on the external cell surface membranes and in the cytoplasmic ground substance of human monocytes by immuno-electron microscopy , 1995, The Journal of experimental medicine.
[94] T. Barbui,et al. Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. , 1991, Blood.
[95] C. Dinarello,et al. Modulation of acute myeloblastic leukemia (AML) cell proliferation and blast colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra). , 1995, Journal of chemotherapy.
[96] C. Dinarello,et al. Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. , 1991, The Journal of clinical investigation.
[97] H. Colten,et al. Structure and function of membrane IL-1. , 1988, Molecular immunology.
[98] S. Durum,et al. Membrane IL-1: IL-1 alpha precursor binds to the plasma membrane via a lectin-like interaction. , 1989, Journal of immunology.
[99] L. Gehrke,et al. Peripheral blood mononuclear cells stimulated with C5a or lipopolysaccharide to synthesize equivalent levels of IL-1 beta mRNA show unequal IL-1 beta protein accumulation but similar polyribosome profiles. , 1994, Journal of immunology.
[100] Z. Estrov,et al. Altered levels of interleukin-1β and interleukin-1 receptor antagonist in chronic myelogenous leukemia: Clinical and prognostic correlates , 1994 .
[101] A. Mantovani,et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. , 1993, Science.
[102] S. Eto,et al. Expression of interleukin 1 receptors on human peripheral T cells. , 1987, Journal of immunology.
[103] A. Levey,et al. In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. , 1992, Kidney international.
[104] Y. Satow,et al. Structure of interleukin 1 alpha at 2.7-A resolution. , 1990, Biochemistry.
[105] R. Locksley,et al. The 31-kDa precursor of interleukin 1 alpha is myristoylated on specific lysines within the 16-kDa N-terminal propiece. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[106] M. Arsura,et al. Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist , 1994 .
[107] Shai Shaham,et al. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme , 1993, Cell.
[108] J. Mier,et al. Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. , 1993, Blood.
[109] J. Mankovich,et al. Crystal structure of the cysteine protease interleukin-1β-converting enzyme: A (p20/p10)2 homodimer , 1994, Cell.
[110] P. Libby,et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. , 1987, Journal of immunology.
[111] H. Amemiya,et al. Recombinant human interleukin‐1 beta analogue as a regulator of hematopoiesis in patients receiving chemotherapy for urogenital cancers , 1991, Cancer.
[112] S. Haskill,et al. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[113] A. Malkinson,et al. Decreased content of the IL1 alpha processing enzyme calpain in murine bone marrow-derived macrophages after treatment with the benzene metabolite hydroquinone. , 1994, Toxicology letters.
[114] A. Mantovani,et al. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. , 1994, Immunology today.
[115] H. Kimball,et al. The effects of hydrocortisone and estrogen on experimental fever induced by etiocholanolone. , 1973, The Journal of infectious diseases.
[116] G. Wong,et al. A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. , 1991, Blood.
[117] E. Guinan,et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease , 1994 .
[118] R. Black,et al. Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme , 1992, Cell.
[119] R. Kastelein,et al. A newly defined interleukin-1? , 1996, Nature.
[120] H. Tilg,et al. Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans. , 1994, Cytokine.
[121] Starnes Hf. Biological effects and possible clinical applications of interleukin 1. , 1991 .
[122] C. Dinarello,et al. Interleukin-1 stimulates diacylglycerol production in T lymphocytes by a novel mechanism , 1988, Cell.
[123] A. Steere,et al. Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis , 1993, The Lancet.
[124] S. Dower,et al. The two interleukin-1 receptors play different roles in IL-1 actions. , 1994, Clinical immunology and immunopathology.
[125] A. Heguy,et al. A chimeric type II/type I interleukin-1 receptor can mediate interleukin-1 induction of gene expression in T cells. , 1993, The Journal of biological chemistry.
[126] J. Saklatvala,et al. IL-1 and TNF transmodulate epidermal growth factor receptors by a protein kinase C-independent mechanism. , 1989, Journal of immunology.
[127] Mark A. Murcko,et al. Structure and mechanism of interleukin-lβ converting enzyme , 1994, Nature.
[128] C. Dinarello,et al. Detection of soluble IL-1 receptor type II (IL-1sRII) in sera and plasma from healthy volunteers , 1994 .
[129] M. Grütter,et al. Crystallographic refinement of interleukin 1 beta at 2.0 A resolution. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[130] H. Okamura,et al. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. , 1996, Journal of immunology.
[131] S. Dower,et al. IL-1 induces rapid phosphorylation of the IL-1 receptor. , 1989, Journal of immunology.
[132] M. Su,et al. Activation of Interferon-γ Inducing Factor Mediated by Interleukin-1β Converting Enzyme , 1997, Science.
[133] R. Kamen,et al. Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock , 1995, Cell.
[134] M. Su,et al. A novel human protease similar to the interleukin‐1 beta converting enzyme induces apoptosis in transfected cells. , 1995, The EMBO journal.
[135] D. Rifkin,et al. Release of basic fibroblast growth factor, an angiogenic factor devoid of secretory signal sequence: A trivial phenomenon or a novel secretion mechanism? , 1991, Journal of cellular biochemistry.
[136] K. O. Elliston,et al. A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes , 1992, Nature.
[137] Z. Estrov,et al. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity , 1991 .
[138] C. Dinarello,et al. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. , 1994, Cancer research.
[139] J. Sims,et al. Genomic organization of the type I and type II IL-1 receptors. , 1995, Cytokine.
[140] C. Dinarello,et al. Coagulation of Whole Blood Stimulates Interleukin-1β Gene Expression , 1995 .
[141] C. Dinarello,et al. Dissociation between interleukin-1 beta mRNA and protein synthesis in human peripheral blood mononuclear cells. , 1990, The Journal of biological chemistry.
[142] C. Dinarello,et al. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. , 1993, Blood.
[143] K. McIntyre,et al. Insertion of a Structural Domain of Interleukin (IL)-1β Confers Agonist Activity to the IL-1 Receptor Antagonist , 1995, The Journal of Biological Chemistry.
[144] F. Cozzolino,et al. Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[145] D. Fuchs,et al. Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation. , 1993, The Journal of thoracic and cardiovascular surgery.
[146] S. Nagata,et al. Involvement of an ICE-like protease in Fas-mediated apoptosis , 1995, Nature.
[147] P. Ghezzi,et al. IL-1 induces IL-1. IV. IFN-gamma suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. , 1990, Journal of immunology.
[148] H. Okamura,et al. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. , 1996, Journal of immunology.
[149] G. Firestein,et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. , 1992, Journal of immunology.
[150] C. Dinarello,et al. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. , 1992, Blood.
[151] M. Oppermann,et al. Gene expression of interleukin-1β during hemodialysis , 1993 .
[152] M. Su,et al. Interleukin‐1 beta converting enzyme requires oligomerization for activity of processed forms in vivo. , 1995, The EMBO journal.
[153] H. Okamura,et al. Endotoxin-induced serum factor that stimulates gamma interferon production , 1989, Infection and immunity.
[154] A. Heguy,et al. Internalization and nuclear localization of interleukin 1 are not sufficient for function. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[155] N. Gay,et al. Drosophila Toll and IL-1 receptor , 1991, Nature.
[156] H. Okamura,et al. Purification of a factor which provides a costimulatory signal for gamma interferon production , 1993, Infection and immunity.
[157] C. March,et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. , 1988, Science.
[158] Junying Yuan,et al. Human ICE/CED-3 Protease Nomenclature , 1996, Cell.
[159] E. Unanue,et al. Identification of a membrane-associated interleukin 1 in macrophages. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[160] S. Dower,et al. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. , 1994, Journal of immunology.
[161] M. Su,et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. , 1995, Science.
[162] K. Huebner,et al. A novel IL‐1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. , 1991, The EMBO journal.
[163] D. Longo,et al. The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin , 1993 .
[164] S. Dower,et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. , 1994, Journal of immunology.
[165] M. Polan,et al. Interleukin-1 in human ovarian cells and in peripheral blood monocytes increases during the luteal phase: evidence for a midcycle surge in the human. , 1994, American journal of obstetrics and gynecology.
[166] H. Starnes,et al. Preliminary report: effects of interleukin-1 on platelet counts , 1990, The Lancet.
[167] S. Dower,et al. Independent binding of interleukin-1 alpha and interleukin-1 beta to type I and type II interleukin-1 receptors. , 1993, The Journal of biological chemistry.
[168] F. Cozzolino,et al. A novel secretory pathway for interleukin‐1 beta, a protein lacking a signal sequence. , 1990, The EMBO journal.
[169] M. Hurme,et al. Synergism between protein-kinase C and cAMP-dependent pathways in the expression of the interleukin-1 beta gene is mediated via the activator-protein-1 (AP-1) enhancer activity. , 1993, European journal of biochemistry.
[170] R. Thompson,et al. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. , 1990, The Journal of clinical investigation.
[171] S. Pongor,et al. Deletion mutants of human interleukin 1 beta with significantly reduced agonist properties: search for the agonist/antagonist switch in ligands to the interleukin 1 receptors. , 1994, Cytokine.
[172] S. Kunkel,et al. Endogenous IL-1 receptor antagonist protein (IRAP) regulates schistosome egg granuloma formation and the regional lymphoid response. , 1993, Journal of immunology.
[173] J. Ihle,et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells , 1994 .
[174] E. Alnemri,et al. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. , 1994, The Journal of biological chemistry.
[175] Alexey G. Murzin,et al. β-Trefoil fold: Patterns of structure and sequence in the Kunitz inhibitors interleukins-1β and 1α and fibroblast growth factors , 1992 .
[176] Antonio Alcami,et al. A soluble receptor for interleukin-1β encoded by vaccinia virus: A novel mechanism of virus modulation of the host response to infection , 1992, Cell.
[177] A. Vander,et al. In vivo evidence that the rise in plasma IL 6 following injection of a fever-inducing dose of LPS is mediated by IL 1 beta. , 1990, Cytokine.
[178] C. Dinarello,et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia , 1991, The Lancet.
[179] A. C. Webb,et al. Human pro-IL-1 beta gene expression in monocytic cells is regulated by two distinct pathways. , 1988, Journal of immunology.
[180] M. Röllinghoff,et al. IL-1 beta is secreted by activated murine macrophages as biologically inactive precursor. , 1990, Journal of immunology.
[181] H. Okamura,et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock , 1995, Infection and immunity.
[182] R. Thompson,et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. , 1991, Blood.
[183] J. Maier,et al. Endogenous interleukin 1 alpha must be transported to the nucleus to exert its activity in human endothelial cells , 1994, Molecular and cellular biology.
[184] A. C. Webb,et al. Multiple biological activities of human recombinant interleukin 1. , 1986, The Journal of clinical investigation.
[185] F. Brennan,et al. Distribution of interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin 1α in normal and psoriatic skin. Decreased expression of IRAP in psoriatic lesional epidermis , 1992, The British journal of dermatology.
[186] E Labriola-Tompkins,et al. Structure-function analysis of human IL-1 alpha: identification of residues required for binding to the human type I IL-1 receptor. , 1993, Protein engineering.
[187] H. Colten,et al. The precursor of interleukin-1 alpha is phosphorylated at residue serine 90. , 1988, The Journal of biological chemistry.
[188] A. Steere,et al. Live Borrelia burgdorferi preferentially activate interleukin-1 beta gene expression and protein synthesis over the interleukin-1 receptor antagonist. , 1992, The Journal of clinical investigation.